Genprex Inc (NASDAQ: GNPX) is headed for the top in the market today, trading on gains of nearly 100% after reporting positive data. Here’s what’s going on:
GNPX Heads Skyward On Positive Clinical Data
In a press release issued early this morning, Genprex announced positive data in some of the most difficult to treat cancers. The data surrounded the combination of TUSC2 immunogene therapy and an anti-PD1 antibody, pembrolizumab as well as the combination of TUSC2 immunogene therapy in combination with pembrolizumab and chemotherapy.
The treatment was assessed as a potential option for some of the most difficult-to-treat metastatic lung cancers. These included KRAS and LKB1 mutations.
Importantly, the TUSC2 gene is a tumor supressor gene and is the active agent in the Oncoprex, an immunogene therapy under development at GNPX.
In the release, the company said that the data showed that TUSC2 confers sensitivity to checkpoint blockade for some of the most resistant metastatic human cancers, in mice with human cells. In fact, the treatment proved to significantly increase antitumor activity when TUSC2 was combined with other treatments when compared to the results from these other treatments alone.
In a statement, Julien L. Pham, MD, MPH, President and CEO at GNPX, had the following to offer:
These data not only further support existing preclinical data showing that Oncoprex immunogene therapy is synergistic with anti-PD1 therapy, but they also offer new data demonstrating that Oncoprex improves on the combination of anti-PD1 therapy and chemotherapy, today’s first line standard of care for lung cancer.
In a sophisticated humanized mouse model, the combination of TUSC2 with pembrolizumab and carboplatin resulted in complete eradication of anti-PD1 resistant lung metastases in some of the most resistant cancer mutations. This is highly encouraging and provides us with a strong indication that the combination could lead to similar results in the clinic.
Why This News Is So Important
Investors are excited here, and for several, very good reasons. Here’s how I see it:
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
Click below to continue reading!